Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;12(21):2831-2837.
doi: 10.1111/1759-7714.14155. Epub 2021 Sep 29.

Primary mediastinal large B cell lymphoma

Yating Yu #  1 , Xifeng Dong #  1 , Meifeng Tu  2 , Huaquan Wang  1
Affiliations
Review

Primary mediastinal large B cell lymphoma

Yating Yu et al. Thorac Cancer. 2021 Nov.

Abstract

Primary mediastinal large B cell lymphoma (PMBCL) is an aggressive large B cell lymphoma originating in the mediastinum, that mainly expresses B cell surface molecules, such as CD19, CD20, CD22, andCD79a. Clinically, they are characterized by rapidly increasing anterior mediastinal masses, which can cause compression of the surrounding tissues. The diagnosis of PMBCL mainly depends on the pathological features, imaging examination and clinical features. Currently, the most commonly used therapeutic regimens are R-CHOP and R-EPOCH. Radiotherapy is beneficial in some patients, but it can also lead to long-term toxicity. The research and development of novel therapies are ongoing, and some studies have achieved encouraging results, including those conducted on chimeric antigen receptor-modified T (CAR-T) cell therapy and anti-PD-1 drugs. However, randomized controlled trials with larger sample sizes are still needed. Positron emission tomography-computed tomography (PET-CT) is mainly used to assess the curative effect after treatment and to guide the subsequent treatment strategy.

Keywords: diagnosis; drug therapy; immunotherapy; primary mediastinal large B-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
(a) Computed tomography (CT) from a male patient who presented with a primary mediastinal large B cell lymphoma. The long arrow shows the mediastinal mass. (b) CT scan from this patient after five cycles of the R‐CHOP regimen. The mediastinal mass decreased significantly
FIGURE 2
FIGURE 2
Management of PMBCL. CR, complete remission; PR, partial remission; PD, progressive disease; SD, stable disease; HDT/ASCR, high‐dose therapy followed by autologous stem cell rescue
See this image and copyright information in PMC

References

    1. Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B‐cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–27. - PubMed
    1. Barth TFE, Leithäuser F, Joos S, Bentz M, Möller P. Mediastinal (thymic) large B‐cell lymphoma: where do we stand? Lancet Oncol. 2002;3(4):229–34. - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. - PMC - PubMed
    1. Pfau D, Smith DA, Beck R, Gilani KA, Gupta A, Caimi P, et al. Primary mediastinal large B‐cell lymphoma: a review for radiologists. Am J Roentgenol. 2019;213(5):W194–210. - PubMed
    1. Giulino‐Roth L. How I treat primary mediastinal B‐cell lymphoma. Blood. 2018;132(8):782–90. - PMC - PubMed

Publication types

MeSH terms